Effects of interleukin-2 and interleukin-2-activated cells on in vitro myelopoiesis
- 1 September 1990
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 81 (3) , 459-465
- https://doi.org/10.1111/j.1365-2249.1990.tb05356.x
Abstract
Lymphokine-activated killer (LAK) cells from human peripheral blood mononuclear cells cultured with recombinant interleukin-2 (IL-2) have been used clinically in adoptive immunotherapy for cancer patients. To study the influence of LAK cells and IL-2 on haematopoiesis, an in vitro assay system for colony formation of granulocyte-macrophage progenitor cells (GM-CFC) was used. LAK cells from cultures of either human peripheral blood (PB) or human bone marrow (BM) mononuclear cells were both inhibitory to allogeneic BM-derived GM-CFC. Inhibitory activity could be transferred with supernatants from co-cultures of LAK cells and BM targets, but also from the IL-2 activated PB- or BM-derived cells alone. The inhibitory activity from the initially non-cytotoxic/non-inhibitory BM population was rapidly induced by IL-2 activation, and preceded the generation of cytotoxic LAK cells in the culture. These experiments show that inhibition of haematopoietic progenitor cells by IL-2 is not dependent on generation of cytotoxic LAK cells, but rather the result of IL-2 induced cytokine production. We conclude that the synergistic action of interferon-gamma (IFN-.gamma.) and tumour necrosis factor-alpha (TNF-.alpha.) may contribute to inhibition, but that also other cytokines are responsible for the observed inhibition of BM-derived GM-CFC.Keywords
This publication has 31 references indexed in Scilit:
- The effects of recombinant interleukin 2-activated natural killer cells on autologous peripheral blood hematopoietic progenitors.The Journal of Experimental Medicine, 1988
- Lymphokine-activated killer cell activity: Characteristics of effector cells and their progenitors in blood and spleenImmunology Today, 1987
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis.The Journal of Experimental Medicine, 1986
- Natural killer (NK) cell-derived hematopoietic colony-inhibiting activity and NK cytotoxic factor. Relationship with tumor necrosis factor and synergism with immune interferon.The Journal of Experimental Medicine, 1985
- Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.The Journal of Experimental Medicine, 1985
- Inhibition of bone marrow colony formation by human natural killer cells and by natural killer cell-derived colony-inhibiting activity.The Journal of Experimental Medicine, 1985
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.The Journal of Experimental Medicine, 1982
- Published by Wiley ,1977
- Human bone marrow colony growth in agar‐gelJournal of Cellular Physiology, 1970